ASPECTS OF TARGET THERAPY IN TRIPLE NEGATIVE BREAST CANCER.

As one goes in deeper into treating Breast cancer with triple negative characteristics, one quickly realize it is imperative to further assess genome and pathway drivers in order to get to effective therapy.  This type of Breast cancer is driven by polygenic stimulators and prognostic factors.  Recent developments has pointed to STAT1 and its relationship with AKT3 and MAP3-K1.  In the article posted here, MAGI3-AKT3 reshuffling is plenty discussed.  One of the challenge is to find an effective AKT3 inhibitor.   The potential inhibitors have been tested in Melanoma where AKT3 pathway is amplified in 70% of cancer cells.  Generally, an amplification of pathways is linked to overexpression of promoter genes and transcription genes.  This is were gene Methylation can help silence these promoters, and can prove an effective way controlling these disease processes. Once again, we believe that an Interfeon and /or Interleukin combined to an mTor (Afinitor), plus or minus a Taxane would be effective in Triple Negative Breast Cancer.